Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Myriad: Q4 Earnings Snapshot
Myriad: Q4 Earnings Snapshot
Associated Press Finance
Tue, February 24, 2026 at 6:52 AM GMT+9 1 min read
In this article:
MYGN
+2.10%
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $7.9 million in its fourth quarter.
The Salt Lake City-based company said it had a loss of 8 cents per share. Earnings, adjusted for costs related to mergers and acquisitions and asset impairment costs, came to 4 cents per share.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 2 cents per share.
The molecular diagnostic company posted revenue of $209.8 million in the period.
For the year, the company reported a loss of $365.9 million, or $3.95 per share. Revenue was reported as $824.5 million.
Myriad expects full-year revenue in the range of $860 million to $880 million.
This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on MYGN at
Terms and Privacy Policy
Privacy Dashboard
More Info